Pancreatic Pharmaceuticals

Pancreatic Pharmaceuticals is spin off company of Micar Innovation, registered in Sofia, Bulgaria. Under terms of the agreement, Micar Innovation grants Pancreatic Pharmaceuticals (Sofia - Bulgaria) an exclusive option to license and develop MIC6479 drugs targeting Pancreatic Cancer disease. Pancreatic Pharmaceuticals capital is in the hands of Micar Innovation driven by impact and provide value to our future investors.

Pancreatic Pharmaceuticals aim

Pancreatic Pharmaceuticals (spin off company of Micar Innovation) is specialized in the discovery, development and commercialization of the small molecule drugs and transforming the treatment of Pancreatic cancer by advancing one of the largest, exclusively cancer-focused clinical pipelines of novel therapies. By using structure based in silico drug design & AI (Micar21 platform) we constructed the best Pancreatic Cancer drug candidate fast & validated.

We aim to bridge the safety and efficacy gaps in current approaches to Pancreatic Cancer management. Pancreatic Pharmaceuticals lead drug candidate, MIC6479, is currently in the phase preclinical for the treatment of Pancreatic Cancer.


Pancreatic cancer begins when abnormal cells within the pancreas grow out of control and form a tumor. The pancreas is a gland in the abdomen that lies behind the stomach and in front of the spine, with two main functions: digestion and blood sugar regulation.

More than 95 percent of pancreatic cancers are classified as exocrine tumors. These tumors start in the exocrine cells that make pancreatic enzymes that help in digestion. Within this category, the vast majority of tumors are adenocarcinomas.

Pancreatic neuroendocrine tumors (pancreatic NETs or PNETs) account for less than 5 percent of all pancreatic tumors. They may be benign or malignant and tend to grow slower than exocrine tumors.